evitria AG, a Zurich, Switzerland-based contract research, development, and manufacturing organization focused on transient recombinant antibody and protein production, announced that former Director of Client Relations, Richard Park, has been appointed Global Head of Client Relations and Business Development.
evitria AG is a subsidiary of Stockholm, Sweden-based Atlas Antibodies, majority owned by Patricia Industries, a part of Investor AB.
“It is an amazing journey evitria has gone through over the past years. The team has done an outstanding job supporting a larger number of customers with our transient expression services. Richard’s leadership will further strengthen the fast-growing Client Relations and Business Development team and allow us to scale our growth while maintaining our commitment to exceptional quality and customer service,” said Christian Eberle, PhD, Chief Executive Officer.
Mr. Park added, “evitria is in the middle of an exciting growth phase with an increasing emphasis on supporting our clients’ antibody and protein production needs across various applications in therapeutics, diagnostics, development, and research. I am proud of the work that our team has collectively accomplished throughout the pandemic, and I am honored by the opportunity to lead our business development efforts and evolve our approach to fit this constantly changing landscape. We have an incredible and growing team, where everyone plays a strategic role in achieving our mission. That is why I joined evitria, and why I look forward to evitria’s future.”
evitria AG
C/O Richard Park
One Broadway, 14th Floor
Cambridge, MA 02142
